Focus on Intellia Therapeutics Upcoming Presentation for NTLA-2001
- Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidate
- Late-breaking abstract selected for oral presentation on June 26
Intellia Therapeutics NTLA-2001 for People Living with hATTR-PN
Intellia Therapeutics (NTLA) announced that Phase 1 . . .
This content is for paid subscribers.
Today’s Highlights June 4, 2021